News & Updates

Show Multimedia Only
Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma

Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma

08 Aug 2024 byStephen Padilla

In patients with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line of therapy (LOT), treatment with belantamab mafodotin (belamaf) plus pomalidomide and dexamethasone (BPD) results in statistically significant and clinically meaningful progressive-free survival (PFS) compared with pomalidomide plus bortezomib and dexamethasone (PVD), as shown in the DREAMM-8 study.

Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma

08 Aug 2024
New risk factor identified for sudden infant death: Maternal obesity

New risk factor identified for sudden infant death: Maternal obesity

08 Aug 2024
Fenofibrate staves off vision loss in diabetes

Fenofibrate staves off vision loss in diabetes

08 Aug 2024 byElvira Manzano

The antilipidemic drug fenofibrate averts or delays diabetic retinopathy (DR) in diabetes patients with early retinal changes in the LENS trial, potentially paving the way for the least invasive route of drug delivery in this population.

Fenofibrate staves off vision loss in diabetes

08 Aug 2024
Dolutegravir plus lamivudine suppresses HIV without HBV reactivation

Dolutegravir plus lamivudine suppresses HIV without HBV reactivation

07 Aug 2024